**Supplemental Table S1**: Overview about administered antiplatelet medication in the participating centers

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Center A | Center B  | Center C | Center D  |
| Prior to stenting | weight-adapted bolus of tirofiban followed by a continuous IV infusion for 24 hours | acetylsalicylic acid 500 mg | weight-adapted bolus of tirofiban followed by a continuous IV infusion for 12 hours | half of the recommended bolus dose (0.125 mg/kg body weight) of abciximab |
| After the procedure |  |  |  | 300 mg acetylsalicylic acid,300 mg clopidogrel |
| After control CT scan\* | 500 mg acetylsalicylic acid,300 mg clopidogrel | 100 mg acetylsalicylic acid,450 mg clopidogrel | 500 mg acetylsalicylic acid,300 mg clopidogrel |  |
| Dual antiplatelet | 6 months100 mg acetylsalicylic acid,75 mg clopidogrelLife-long100 mg acetylsalicylic acid | 6 weeks100 mg acetylsalicylic acid,75 mg clopidogrelLife-long100 mg acetylsalicylic acid | 3 months100 mg acetylsalicylic acid,75 mg clopidogrelLife-long100 mg acetylsalicylic acid | 3 month75 mg clopidogrel6 month acetylsalicylic acid |

\* when routine follow-up CT scan did not reveal a significant hematoma